---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-053982"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:37:08.001388+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns

## Summary
- Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.
- Svetlana Lucas, Ph.D., appointed as Class III director effective June 18, 2024.
- Lucas is Chief Business Officer at Scribe Therapeutics with 20+ years in biopharma strategy.
- Received initial option grant of 15,000 shares at $23.19/share, vesting over 4 years.
- Also serves on board of aTyr Pharma (Nasdaq: LIFE) and as advisor to Radar Therapeutics.

## SEC filing metadata
- accession: 0001213900-24-053982
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/ea0208074-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-053982
- JSON: https://secwatch.observer/filing/0001213900-24-053982.json
- Plain text: https://secwatch.observer/filing/0001213900-24-053982.txt

## Source-grounded claims
- claim_id: 932297e83c
  claim: Anna French resigned as Director at Jasper Therapeutics, Inc..
  evidence_excerpt: On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm
- claim_id: a571f3aa62
  claim: Svetlana Lucas was appointed as Class III Director at Jasper Therapeutics, Inc..
  evidence_excerpt: Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.